A pharmaceutical website redesign can fail while looking excellent. The interface may be modern, the new component library polished and the CMS easier to use, yet the programme can still create regulatory bottlenecks, accessibility regressions, lost SEO equity, inconsistent market pages and an approval process that is harder than the one it replaced.
The difference between a visual redesign and a robust pharma website design programme is governance. Before designing templates, teams need to know who owns content, how MLR review will work, which parts are global or local, how consent affects analytics, what accessibility level is required and how releases will be validated.
Start with an inventory of domains, markets, brands, disease sites, HCP areas, patient resources, campaign microsites and legacy platforms. Record owner, technology, language, traffic, purpose, regulatory status and planned lifespan.
This prevents a redesign from solving one property while increasing fragmentation elsewhere. It also identifies consolidation opportunities and dependencies such as shared consent management, authentication or analytics.
Every important content type needs a business owner and an approval route. Corporate pages may be communications-owned, scientific content may involve medical, HCP resources may include commercial or medical teams, and privacy or safety information may have specialist owners.
Write this down before migration. A CMS cannot solve ambiguous responsibility. If nobody knows who can approve a page, the new workflow will stall regardless of technology.
Review should not happen only at the end. Identify components likely to contain claims, references, fair-balance information, safety text, product names or market-specific language. Determine which modules can be reused under an existing approval and which require new review when context changes.
Store approval metadata where possible: review status, reference set, owner, market, approval date and revalidation date. The CMS should make it easier to know whether content is current.
Global teams often want consistency while affiliates need regulatory and market flexibility. Define which layers are shared: design tokens, core components, corporate facts, certain scientific assets or technical standards. Then define what markets can localise: copy, product availability, contact details, legal text, navigation or approved modules.
A rigid global template can cause markets to create workarounds. An unconstrained model creates fragmentation. Governance should state what can change and how.
Do not treat accessibility as a final audit. Define component requirements for keyboard operation, focus order, labels, heading hierarchy, contrast, form errors, modal behaviour, video controls and alternative text. Test design-system components before they are multiplied across hundreds of pages.
Accessibility also improves editorial discipline. Clear headings, descriptive links and understandable error messages help all users and create cleaner machine-readable content.
Map cookies, tags, embeds and external services. Define which are necessary, which require consent and what the fallback experience is when a user declines. A video, map or form should not simply disappear without explanation.
Consent mode and tag-management behaviour need technical QA. Verify that analytics does not fire unlawfully, but also that essential site functions remain available.
List the decisions measurement should support. This may include disease-content engagement, HCP resource use, medical-information journeys, form completion, search behaviour, document downloads and market performance.
Define a consistent data layer and event taxonomy. If every market invents its own event names, global reporting becomes unreliable. Validate events in staging with consent states.
For every existing URL, choose keep, rewrite, merge, redirect, archive or retire. Add owner, approval status and destination. This becomes the backbone of both content migration and SEO redirect mapping.
Do not copy legacy content automatically just because it exists. A redesign is an opportunity to remove expired pages and duplication, but retirement should be deliberate and traceable.
Export current organic landing pages, backlinks, indexable URLs, XML sitemaps and important query data. Build one-to-one redirects where a true equivalent exists. Avoid redirecting large groups of unrelated URLs to the home page.
Validate canonicals, robots directives, hreflang, structured data, metadata and status codes before launch. Compare crawl results between current and staging versions.
Documents often have version, market, audience and approval metadata. The redesign should avoid treating them as generic media files. Define a document content type with expiry, language, product or disease association and replacement relationships.
When a file is superseded, decide whether the URL remains stable, redirects or displays an archive state. Search engines and users should not find uncontrolled outdated versions.
If the estate includes HCP areas, document verification rules, market eligibility, session behaviour, password recovery, privacy and what happens when an HCP changes country. Authentication is a business and compliance workflow as much as a technical feature.
Test failure states. A valid professional who cannot complete verification needs a clear route to support without exposing restricted content.
Translation involves source version, translator, reviewer, market adaptation and synchronisation. Decide what happens when the global source changes after a local page has been approved. The CMS should signal that a translation may be outdated without automatically overwriting reviewed local content.
Use terminology libraries for product, scientific and legal language. Machine translation can assist low-risk workflow stages, but review requirements should be explicit.
A CMS with only administrator and editor roles is rarely enough for a global pharma estate. Consider authors, reviewers, publishers, market managers, translators and technical administrators. Apply least privilege.
Keep an audit trail for significant changes and publication. Offboarding should remove access promptly, particularly for agency and temporary users.
Not every change needs the same process. Separate low-risk editorial corrections, approved-component reuse, template changes and new functionality. Create release criteria and QA requirements for each class.
This prevents a simple typo fix from waiting for a major release while ensuring a consent or authentication change receives appropriate testing.
Before go-live, collect evidence: accessibility test results, MLR sign-offs, privacy review, consent tests, analytics validation, redirect checks, browser/device QA, security findings and rollback plan. The objective is not bureaucracy. It is to know what was tested and who accepted residual risks.
Monitor 404s, crawl errors, form failures, consent anomalies, analytics gaps, performance, authentication and user feedback. Search engines may take days or weeks to reflect migration changes, so SEO monitoring continues after launch.
Establish daily review during the first week and a structured stabilisation backlog. Do not disperse the launch team immediately after DNS changes.
One benefit of a design system is repeatability, but reviewers need to know when content is reused unchanged versus modified. Give reusable modules stable identifiers and approval metadata. This can reduce unnecessary re-review when policy permits.
A redesign is incomplete while the old environment remains publicly reachable or editable without purpose. Plan redirects, DNS, archive, access removal, backups and data-retention decisions. Old staging sites and forgotten microsites can become security and compliance risks.
A dashboard turns governance from a yearly audit into an operating process.
MLR requirements should inform the architecture, but information design also needs to serve users, accessibility and technical maintainability. The best model brings these needs together early.
Yes, when permissions, content inheritance, localisation and market-specific governance are designed deliberately. A single platform does not require identical content in every market.
Throughout design and development. Component-level testing early is far more efficient than discovering systemic problems after content migration.
A pharma redesign is safer when governance is specified as part of the product rather than added after launch. Define who owns each page family, which content requires medical, legal or regulatory review, which components may be reused without reopening the full approval chain, and what evidence must travel with each claim. The same model should cover localisation: affiliates need clear rules for what they may adapt, what must remain globally controlled and how country-specific prescribing, safety or legal information is handled.
It is also worth agreeing the operational evidence trail before templates are final. Teams should be able to identify the source of a claim, its approval status, the market where it is valid and the date on which it should be reviewed again. That makes the redesigned website easier to maintain and reduces the risk that attractive new layouts create a content-governance problem six months later.